VEGFA and cancer: Cancer cells resist and adapt to inhibit the immune system by releasing immunosuppressive mediators (prostaglandin E2 [PGE2], TGF-β, IL-10, and vascular endothelial growth factor [VEGF]) against immune surveillance.